Nephrology

Back to articles

Anemia, ESA guidelines under revision

KEY POINT

Anemia management in patients with chronic kidney disease—especially the recommended target hemoglobin at which erythropoiesis stimulating agents (ESA) such as epoetin alfa (Epogen—Amgen; Procrit—Ortho Biotech) and darbepoetin alfa (Aranesp—Amgen) are used—is undergoing review by the National Kidney Foundation.